Literature DB >> 12502814

Identification of immunodominant epitopes derived from the respiratory syncytial virus fusion protein that are recognized by human CD4 T cells.

Grada M van Bleek1, Martien C Poelen, Robbert van der Most, Humphrey F Brugghe, Hans A M Timmermans, Claire J Boog, Peter Hoogerhout, Henny G Otten, Cécile A C M van Els.   

Abstract

Memory CD4 T-cell responses against respiratory syncytial virus (RSV) were evaluated in peripheral blood mononuclear cells of healthy blood donors with gamma interferon enzyme-linked immunospot (Elispot) assays. RSV-specific responses were detected in every donor at levels varying between 0.05 and 0.3% of CD4 T cells. For all donors tested, a considerable component of the CD4 T-cell response was directed against the fusion (F) protein of RSV. We characterized a set of 31 immunodominant antigenic peptides targeted by CD4 T cells in the context of the most prevalent HLA class II molecules within the Caucasian population. Most antigenic peptides were HLA-DR restricted, whereas two dominant DQ peptides were also identified. The antigenic peptides identified were located across the entire sequence of the F protein. Several peptides were presented by more than one major histocompatibility complex class II molecule. Furthermore, most donors recognized several F peptides. Detailed knowledge about immunodominant antigenic peptides will facilitate the ability to monitor CD4 T-cell responses in patients and the measurement of correlates of protection in vaccinated subjects.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12502814      PMCID: PMC140824          DOI: 10.1128/jvi.77.2.980-988.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  50 in total

1.  HLA-DRB1,3,4,5 and -DQB1 allele frequencies and HLA-DR/DQ linkage disequilibrium of 231 German caucasoid patients and their corresponding 821 potential unrelated stem cell transplants.

Authors:  A J Knipper; P Hakenberg; J Enczmann; A Kuhröber; U Kiesel; G Kögler; P Wernet
Journal:  Hum Immunol       Date:  2000-06       Impact factor: 2.850

2.  Pulmonary eosinophilic response to respiratory syncytial virus infection in mice sensitized to the major surface glycoprotein G.

Authors:  P J Openshaw; S L Clarke; F M Record
Journal:  Int Immunol       Date:  1992-04       Impact factor: 4.823

3.  Human cytotoxic T cells stimulated by antigen on dendritic cells recognize the N, SH, F, M, 22K, and 1b proteins of respiratory syncytial virus.

Authors:  A H Cherrie; K Anderson; G W Wertz; P J Openshaw
Journal:  J Virol       Date:  1992-04       Impact factor: 5.103

4.  CD4+ T cells clear virus but augment disease in mice infected with respiratory syncytial virus. Comparison with the effects of CD8+ T cells.

Authors:  W H Alwan; F M Record; P J Openshaw
Journal:  Clin Exp Immunol       Date:  1992-06       Impact factor: 4.330

5.  Role of T lymphocyte subsets in the pathogenesis of primary infection and rechallenge with respiratory syncytial virus in mice.

Authors:  B S Graham; L A Bunton; P F Wright; D T Karzon
Journal:  J Clin Invest       Date:  1991-09       Impact factor: 14.808

6.  Distinct patterns of T- and B-cell immunity to respiratory syncytial virus induced by individual viral proteins.

Authors:  W H Alwan; P J Openshaw
Journal:  Vaccine       Date:  1993       Impact factor: 3.641

7.  Pulmonary histopathology induced by respiratory syncytial virus (RSV) challenge of formalin-inactivated RSV-immunized BALB/c mice is abrogated by depletion of CD4+ T cells.

Authors:  M Connors; A B Kulkarni; C Y Firestone; K L Holmes; H C Morse; A V Sotnikov; B R Murphy
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

8.  Phenotypic and functional characterization of T cell lines specific for individual respiratory syncytial virus proteins.

Authors:  W H Alwan; F M Record; P J Openshaw
Journal:  J Immunol       Date:  1993-06-15       Impact factor: 5.422

9.  Recognition of respiratory syncytial (RS) virus proteins by human and BALB/C CD4+ lymphocytes.

Authors:  J J Anderson; J A Harrop; H Peers; T Turnbull; G L Toms; R Scott
Journal:  J Med Virol       Date:  1991-11       Impact factor: 2.327

10.  Distinct types of lung disease caused by functional subsets of antiviral T cells.

Authors:  W H Alwan; W J Kozlowska; P J Openshaw
Journal:  J Exp Med       Date:  1994-01-01       Impact factor: 14.307

View more
  10 in total

1.  Adults 65 years old and older have reduced numbers of functional memory T cells to respiratory syncytial virus fusion protein.

Authors:  Anu Cherukuri; Kathryn Patton; Robert A Gasser; Fengrong Zuo; Jennifer Woo; Mark T Esser; Roderick S Tang
Journal:  Clin Vaccine Immunol       Date:  2012-12-12

2.  Structural and Nonstructural Viral Proteins Are Targets of T-Helper Immune Response against Human Respiratory Syncytial Virus.

Authors:  Elena Lorente; Alejandro Barriga; Eilon Barnea; Carmen Mir; John A Gebe; Arie Admon; Daniel López
Journal:  Mol Cell Proteomics       Date:  2016-04-18       Impact factor: 5.911

Review 3.  Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus.

Authors:  Matthew R Olson; Steven M Varga
Journal:  Expert Rev Vaccines       Date:  2008-10       Impact factor: 5.217

4.  Identification of a common HLA-DP4-restricted T-cell epitope in the conserved region of the respiratory syncytial virus G protein.

Authors:  L de Waal; S Yüksel; A H Brandenburg; J P M Langedijk; K Sintnicolaas; G M G M Verjans; A D M E Osterhaus; R L de Swart
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

5.  Chimpanzee adenovirus- and MVA-vectored respiratory syncytial virus vaccine is safe and immunogenic in adults.

Authors:  Christopher A Green; Elisa Scarselli; Charles J Sande; Amber J Thompson; Catherine M de Lara; Kathryn S Taylor; Kathryn Haworth; Mariarosaria Del Sorbo; Brian Angus; Loredana Siani; Stefania Di Marco; Cinzia Traboni; Antonella Folgori; Stefano Colloca; Stefania Capone; Alessandra Vitelli; Riccardo Cortese; Paul Klenerman; Alfredo Nicosia; Andrew J Pollard
Journal:  Sci Transl Med       Date:  2015-08-12       Impact factor: 17.956

6.  RSV fusion (F) protein DNA vaccine provides partial protection against viral infection.

Authors:  Hongzhuan Wu; Vida A Dennis; Shreekumar R Pillai; Shree R Singh
Journal:  Virus Res       Date:  2009-06-21       Impact factor: 3.303

Review 7.  Nanoparticle vaccines against respiratory syncytial virus.

Authors:  Laura M Stephens; Steven M Varga
Journal:  Future Virol       Date:  2020-11-30       Impact factor: 1.831

8.  Respiratory syncytial virus human experimental infection model: provenance, production, and sequence of low-passaged memphis-37 challenge virus.

Authors:  Young-In Kim; John P DeVincenzo; Bart G Jones; Rajeev Rudraraju; Lisa Harrison; Rachel Meyers; Jeff Cehelsky; Rene Alvarez; Julia L Hurwitz
Journal:  PLoS One       Date:  2014-11-21       Impact factor: 3.240

9.  Epitope-specific airway-resident CD4+ T cell dynamics during experimental human RSV infection.

Authors:  Aleks Guvenel; Agnieszka Jozwik; Stephanie Ascough; Seng Kuong Ung; Suzanna Paterson; Mohini Kalyan; Zoe Gardener; Emma Bergstrom; Satwik Kar; Maximillian S Habibi; Allan Paras; Jie Zhu; Mirae Park; Jaideep Dhariwal; Mark Almond; Ernie Hc Wong; Annemarie Sykes; Jerico Del Rosario; Maria-Belen Trujillo-Torralbo; Patrick Mallia; John Sidney; Bjoern Peters; Onn Min Kon; Alessandro Sette; Sebastian L Johnston; Peter J Openshaw; Christopher Chiu
Journal:  J Clin Invest       Date:  2020-01-02       Impact factor: 14.808

Review 10.  Neonatal calf infection with respiratory syncytial virus: drawing parallels to the disease in human infants.

Authors:  Randy E Sacco; Jodi L McGill; Mitchell V Palmer; John D Lippolis; Timothy A Reinhardt; Brian J Nonnecke
Journal:  Viruses       Date:  2012-12       Impact factor: 5.048

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.